FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck - PubMed (original) (raw)
FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
Rodney J Taylor et al. Cancer Immunol Immunother. 2009 Jul.
Erratum in
- Cancer Immunol Immunother. 2009 Sep;58(9):1527-8
Abstract
Purpose: The interaction of Fc fragments of antibodies with the Fcgamma receptors is an essential checkpoint in antibody-dependent cellular cytotoxicity (ADCC). Specific polymorphisms at position 158 enhance FcgammaRIIIa affinity for IgG1 and are associated with improved clinical outcome in lymphoma patients treated with IgG1 anti-CD20 antibody. The role of ADCC in the therapeutic effects of the alpha-epidermal growth factor receptor (EGFR) mAb, cetuximab, in patients with squamous cell carcinoma of the head and neck (SCCHN) is poorly defined. We employed three SCCHN cell lines to test two hypotheses: (1) SCCHN is susceptible to cetuximab-mediated ADCC, (2) efficacy of ADCC is associated with polymorphisms at position 158 of FcgammaRIIIa.
Experimental design: FcgammaRIIIa-158 polymorphisms were determined for healthy donors, and their purified NK cells were used as effector cells against three SCCHN cell lines in ADCC assays. Cytotoxicity levels were compared for each polymorphism class. Proliferation and cell cycle assays were done to examine the direct effects of cetuximab.
Results: Our results indicate that SCCHN is susceptible to cetuximab-mediated ADCC in vitro. NK cytotoxic efficiency correlates with donor 158-polymorphisms in FcgammaRIIIa. Overall cytotoxicity was greatest for individuals having a single V allele when compared to homozygous F/F individuals; the cumulative percent cytotoxicity for each polymorphism among the cell lines was 58.2% V/V, 50.6% V/F, and 26.1% F/F (P < 0.001). Additionally, the presence of a V allele correlated with superior natural cytotoxicity against NK sensitive targets.
Conclusion: These data have both prognostic and therapeutic relevance and support the design of a prospective trial to determine the influence of FcgammaRIIIa polymorphisms on the clinical outcome of patients with SCCHN treated with alpha-EGFR mAbs.
Figures
Fig. 1
Epidermal growth factor receptor expression in SCCHN tumor cell lines. SCCHN cell lines TU167, TU59, and 012SCC were stained with a α-EGFR mAb (clone ICR10) with an IgG2a isotype control and b Cetuximab with human IgG1 isotype control. Open histograms represent the isotype control. Filled histograms represent the mAbs staining. All cell lines show a comparable shift for both α-EGFR and cetuximab mAbs
Fig. 2
NK FcγRIIIa polymorphisms influencing cytotoxic activity on cetuximab-treated SCCHN TU167. a NK cells purified from PBMCs of healthy donors expressing either F/F, V/F, or V/V alleles were tested for cytotoxicity against TU167 in a standard 51Cr-release assay. Before addition of effector cells, TU167 target cells were pretreated with media alone (dark filled diamond), human IgG1 isotype control at 10 μg/ml (dark filled square), or cetuximab 10 μg/ml (dark filled triangle). Data are representative of independent experiments performed in triplicates, with error bars indicating SEM. b NK cells purified from PBMCs of 17 individual donors F/F (open diamond), V/F (open square), and V/V (open triangle) alleles were tested for cytotoxicity against the TU167 SCCHN cell line using a standard 51Cr-release assay. Before addition of effector cells TU167 targets were pretreated with media alone, human IgG1 isotype control at 10 μg/ml, or cetuximab at 10 μg/ml. Donors with either FcγRIIIa V/V or FcγRIIIa V/F demonstrated significantly higher percent cytotoxicity compared to FcγRIIIa F/F, when incubated with 10 μg/ml cetuximab (P = 0.04 and 0.004, respectively)
Fig. 3
FcγIIIaR V polymorphism is associated with enhanced natural cytotoxicity against K562 tumor targets. Tumor cell line K562 was subjected to direct NK cytotoxicity in the absence of antibody. Shown here, NK cells from healthy donors bearing FcγIIIaR F/F (open diamond), V/F (open square), and V/V (open triangle) alleles were tested for cytotoxicity against K562 using a standard 51Cr-release assay
Fig. 4
Dose-dependent anti-proliferative activity of cetuximab measured by [3H] thymidine assays. TU159 cell line was cultured in the presence of various concentrations of cetuximab for 72 h. Proliferation was measured by thymidine incorporation. Cetuximab significantly inhibited TU159 in a dose-dependent fashion
Fig. 5
Cell cycling and DNA synthesis activity of TU159 with 10 μg/ml cetuximab. Panels a, b, and c indicate representative experiments for TU159 in media alone, 10 μg/ml isotype control or 10 μg/ml cetuximab respectively. With cetuximab incubation, an increase in phase G2 + M (P5 quadrant) was observed compared to isotype control. S-phase (P6 quadrant) was decreased by at least twofold in panel c compared to panels a and b
Similar articles
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells.
López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. López-Albaitero A, et al. Cancer Immunol Immunother. 2009 Nov;58(11):1853-64. doi: 10.1007/s00262-009-0697-4. Epub 2009 Mar 25. Cancer Immunol Immunother. 2009. PMID: 19319529 Free PMC article. - Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E, Jaime-Ramirez AC, Bhave N, Roda J, Choudhary MM, Kumar B, Teknos TN, Carson WE 3rd. Luedke E, et al. Surgery. 2012 Sep;152(3):431-40. doi: 10.1016/j.surg.2012.05.035. Epub 2012 Jul 6. Surgery. 2012. PMID: 22770960 Free PMC article. - Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Taylor RJ, Saloura V, Jain A, Goloubeva O, Wong S, Kronsberg S, Nagilla M, Silpino L, de Souza J, Seiwert T, Vokes E, Villaflor V, Cohen EE. Taylor RJ, et al. Cancer Immunol Res. 2015 May;3(5):567-74. doi: 10.1158/2326-6066.CIR-14-0188. Epub 2015 Mar 13. Cancer Immunol Res. 2015. PMID: 25769300 Free PMC article. Clinical Trial. - Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Bauman JE, Ferris RL. Bauman JE, et al. Cancer. 2014 Mar 1;120(5):624-32. doi: 10.1002/cncr.28380. Epub 2013 Nov 12. Cancer. 2014. PMID: 24222079 Free PMC article. Review. - Immune biomarkers of anti-EGFR monoclonal antibody therapy.
Trivedi S, Concha-Benavente F, Srivastava RM, Jie HB, Gibson SP, Schmitt NC, Ferris RL. Trivedi S, et al. Ann Oncol. 2015 Jan;26(1):40-47. doi: 10.1093/annonc/mdu156. Epub 2014 Jul 4. Ann Oncol. 2015. PMID: 24997207 Free PMC article. Review.
Cited by
- Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma.
Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K, Liu P, Yu S, Ma J, He H. Dong S, et al. Front Immunol. 2024 Aug 21;15:1442673. doi: 10.3389/fimmu.2024.1442673. eCollection 2024. Front Immunol. 2024. PMID: 39234249 Free PMC article. Review. - NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3.
Freitas Monteiro M, Papaserafeim M, Andreani M, Réal A, Kouklas A, Reis Galvão D, Seebach JD, Puga Yung GL. Freitas Monteiro M, et al. Antibodies (Basel). 2024 Jul 12;13(3):55. doi: 10.3390/antib13030055. Antibodies (Basel). 2024. PMID: 39051331 Free PMC article. - Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M, Arlen PM, Tsang KY. Fantini M, et al. Front Immunol. 2023 Nov 24;14:1275904. doi: 10.3389/fimmu.2023.1275904. eCollection 2023. Front Immunol. 2023. PMID: 38077389 Free PMC article. Review. - Complement component C1q is an immunological rheostat that regulates Fc:Fc[Formula: see text]R interactions.
So EC, Zhou H, Greenwell A, Burch EE, Ji Y, Mérigeon EY, Olsen HS, Bentzen SM, Block DS, Zhang X, Strome SE. So EC, et al. Immunogenetics. 2023 Aug;75(4):369-383. doi: 10.1007/s00251-023-01311-x. Epub 2023 Jun 15. Immunogenetics. 2023. PMID: 37322230 - Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial.
Gulati S, Crist M, Riaz MK, Takiar V, Lehn M, Monroe I, Palackdharry S, Kurtzweil N, Jandarov R, Harun N, Wise-Draper TM. Gulati S, et al. Clin Cancer Res. 2023 May 15;29(10):1906-1915. doi: 10.1158/1078-0432.CCR-22-3886. Clin Cancer Res. 2023. PMID: 36802410 Free PMC article. Clinical Trial.
References
- Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–7356. - PubMed
- Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94:259–267. doi: 10.1038/sj.bjc.6602930. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous